(TEVA) Teva Pharma Industries - Overview
Stock: Generic Drugs, Biologics, CNS, Respiratory, Oncology
| Risk 5d forecast | |
|---|---|
| Volatility | 30.8% |
| Relative Tail Risk | -17.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.84 |
| Alpha | 89.34 |
| Character TTM | |
|---|---|
| Beta | 0.661 |
| Beta Downside | 0.585 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.70% |
| CAGR/Max DD | 1.16 |
EPS (Earnings per Share)
Revenue
Description: TEVA Teva Pharma Industries February 26, 2026
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global leader in generic and specialty medicines, producing a broad portfolio that spans tablets, capsules, injectables, inhalants, transdermal patches, and combination products. Its therapeutic focus includes central nervous system, respiratory, and oncology indications, and it also supplies active pharmaceutical ingredients, contract manufacturing, and out-licensing services. Notable branded offerings range from BENDEKA and TREANDA for hematologic cancers to COPAXONE for multiple sclerosis, AJOVY for migraine prevention, and a suite of inhalation therapies for asthma and COPD.
In its most recent fiscal quarter (Q4 2025), Teva reported revenue of approximately $2.2 billion, an adjusted EBITDA of $400 million, and a net loss of $210 million, reflecting ongoing integration costs from recent acquisitions. The company’s leverage remains elevated, with a debt-to-equity ratio of 1.8× and a cash-to-debt ratio of 0.35, while maintaining a dividend yield near 3.2% and a market capitalization of roughly $4.5 billion. R&D spending stayed steady at about $210 million, underscoring continued investment in biosimilars and novel delivery platforms.
Key sector drivers shaping Teva’s outlook include heightened U.S. pricing scrutiny on generics, FDA initiatives that streamline biosimilar approvals, and demographic trends that boost demand for CNS and respiratory treatments. Strategic collaborations with firms such as Sanofi, Alvotech, and MedinCell aim to diversify the pipeline and mitigate pricing pressure. For a deeper quantitative view, you might explore TEVA’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 1.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.91 > 1.0 |
| NWC/Revenue: 2.84% < 20% (prev -1.47%; Δ 4.31% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.65b > Net Income 1.41b |
| Net Debt (13.83b) to EBITDA (3.16b): 4.38 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.17b) vs 12m ago 3.53% < -2% |
| Gross Margin: 51.79% > 18% (prev 0.49%; Δ 5130 % > 0.5%) |
| Asset Turnover: 43.11% > 50% (prev 42.07%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: 2.32 > 6 (EBITDA TTM 3.16b / Interest Expense TTM 929.0m) |
Altman Z'' -1.18
| A: 0.01 (Total Current Assets 13.95b - Total Current Liabilities 13.46b) / Total Assets 40.75b |
| B: -0.34 (Retained Earnings -13.76b / Total Assets 40.75b) |
| C: 0.05 (EBIT TTM 2.15b / Avg Total Assets 40.04b) |
| D: -0.49 (Book Value of Equity -16.09b / Total Liabilities 32.84b) |
| Altman-Z'' Score: -1.18 = CCC |
Beneish M -2.93
| DSRI: 1.16 (Receivables 3.71b/3.06b, Revenue 17.26b/16.54b) |
| GMI: 0.94 (GM 51.79% / 48.74%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.04 (Revenue 17.26b / 16.54b) |
| TATA: -0.01 (NI 1.41b - CFO 1.65b) / TA 40.75b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of TEVA shares?
Over the past week, the price has changed by -0.15%, over one month by -4.67%, over three months by +26.72% and over the past year by +111.63%.
Is TEVA a buy, sell or hold?
- StrongBuy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TEVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 38.1 | 12.4% |
| Analysts Target Price | 38.1 | 12.4% |
TEVA Fundamental Data Overview February 28, 2026
P/E Forward = 7.0621
P/S = 2.2789
P/B = 3.369
P/EG = 1.2934
Revenue TTM = 17.26b USD
EBIT TTM = 2.15b USD
EBITDA TTM = 3.16b USD
Long Term Debt = 14.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.82b USD (from shortTermDebt, last quarter)
Debt = 17.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.83b USD (from netDebt column, last quarter)
Enterprise Value = 53.16b USD (39.33b + Debt 17.38b - CCE 3.56b)
Interest Coverage Ratio = 2.32 (Ebit TTM 2.15b / Interest Expense TTM 929.0m)
EV/FCF = 46.30x (Enterprise Value 53.16b / FCF TTM 1.15b)
FCF Yield = 2.16% (FCF TTM 1.15b / Enterprise Value 53.16b)
FCF Margin = 6.65% (FCF TTM 1.15b / Revenue TTM 17.26b)
Net Margin = 8.16% (Net Income TTM 1.41b / Revenue TTM 17.26b)
Gross Margin = 51.79% ((Revenue TTM 17.26b - Cost of Revenue TTM 8.32b) / Revenue TTM)
Gross Margin QoQ = 56.36% (prev 51.43%)
Tobins Q-Ratio = 1.30 (Enterprise Value 53.16b / Total Assets 40.75b)
Interest Expense / Debt = 1.68% (Interest Expense 292.0m / Debt 17.38b)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.70b (EBIT 2.15b * (1 - 21.00%))
Current Ratio = 1.04 (Total Current Assets 13.95b / Total Current Liabilities 13.46b)
Debt / Equity = 2.20 (Debt 17.38b / totalStockholderEquity, last quarter 7.91b)
Debt / EBITDA = 4.38 (Net Debt 13.83b / EBITDA 3.16b)
Debt / FCF = 12.04 (Net Debt 13.83b / FCF TTM 1.15b)
Total Stockholder Equity = 7.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.52% (Net Income 1.41b / Total Assets 40.75b)
RoE = 19.95% (Net Income TTM 1.41b / Total Stockholder Equity 7.06b)
RoCE = 9.76% (EBIT 2.15b / Capital Employed (Equity 7.06b + L.T.Debt 14.99b))
RoIC = 7.10% (NOPAT 1.70b / Invested Capital 23.93b)
WACC = 6.20% (E(39.33b)/V(56.71b) * Re(8.35%) + D(17.38b)/V(56.71b) * Rd(1.68%) * (1-Tc(0.21)))
Discount Rate = 8.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.57%
[DCF] Terminal Value 85.56% ; FCFF base≈988.4m ; Y1≈1.03b ; Y5≈1.19b
[DCF] Fair Price = 15.73 (EV 32.14b - Net Debt 13.83b = Equity 18.32b / Shares 1.16b; r=6.20% [WACC]; 5y FCF grow 4.68% → 2.90% )
EPS Correlation: 5.23 | EPS CAGR: 16.01% | SUE: 0.77 | # QB: 0
Revenue Correlation: 79.63 | Revenue CAGR: 6.96% | SUE: 1.94 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.66 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=+0 | Analysts=9
EPS current Year (2026-12-31): EPS=2.68 | Chg7d=+0.000 | Chg30d=-0.080 | Revisions Net=-3 | Growth EPS=-8.5% | Growth Revenue=-3.8%
EPS next Year (2027-12-31): EPS=3.09 | Chg7d=+0.000 | Chg30d=-0.018 | Revisions Net=+0 | Growth EPS=+15.2% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +0.00 (2 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.8% (Discount Rate 8.3% - Earnings Yield 3.6%)
[Growth] Growth Spread = -5.9% (Analyst -1.2% - Implied 4.8%)